Abstract:Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy, runny, stuffy nose, may have a negative impact on patients’ daily functioning. Omalizumab is being developed as a new choice for the treatment of AR. We therefore undertook a meta-analysis to assess the efficacy and safety of omalizumab in the treatment of AR. Methods We systematically searched PubMed, Cochrane Library, and MEDLINE databases for randomized controlled studies on the treatment of AR with omalizumab. Our evaluation outcomes were symptom scores, medication efficacy, combined symptom and medication scores, and adverse events. We descriptively summarized and quantitatively synthesized original data to evaluate the efficacy and safety of omalizumab in the treatment of AR by using Stata12.0 software for meta-analyses. Results The results of our meta-analysis showed that there were statistically significant differences between the omalizumab group and the control group in the following aspects: daily nasal symptom score (standardized mean difference [SMD] = –0.443, 95% confidence interval [CI]: –0.538 to –0.347, P < .001); daily ocular symptom score (SMD = –0.385, 95% CI: –0.5 to –0.269, P < .001); daily nasal medication symptom scores (SMD = –0.421, 95% CI: –0.591 to –0.251, P < .001); proportion of days of emergency drug use (risk ratio [RR] = 0.488, 95% CI: 0.307 to 0.788, P < .005); rhinoconjunctivitis-specific quality of life questionnaire (SMD = –0.286, 95% CI: –0.418 to –0.154, P < .001); and overall evaluation (RR = 1.435, 95% CI: 1.303–1.582, P < .001). There was no statistically significant difference in safety indicator: adverse events (RR = 1.026, 95% CI: 0.916–1.150, P = .655). Conclusion Omalizumab is effective and relatively safe in patients with AR; omalizumab used in conjunction with special immunotherapy has shown promising results, especially in reducing adverse events.

Mometasone Furoate Nasal Spray Reduces Symptoms and Improves Quality of Life in Chinese Patients with Moderate to Severe Allergic Rhinitis: a Multicenter Open-Label Study.

[Clinical Study on Mometasone Furoate Nasal Spray in the Treatment of Non-Allergic Rhinitis].

Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial

Efficacy and Safety of Fluticasone Furoate Nasal Spray in Chinese Adult and Adolescent Subjects with Intermittent or Persistent Allergic Rhinitis

A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis

[Effect of Topical Steroid on Oral and Nasal Nitric Oxide Production in Patients with Allergic Rhinitis].

Efficacy of mometasone furoate nasal spray in the treatment of acute rhinosinusitis

A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis

Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study

Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis: a Randomized Controlled Trial

Efficacy of Acupuncture on Moderate and Severe Allergic Rhinitis

Acupuncture for Moderate to Severe Allergic Rhinitis: A Non-Randomized Controlled Trial.

Clinical Research on the Quality of Life in Patients with Allergic Rhinitis

Efficacy of intranasal fluticasone propionate nano nasal spray in management of chronic rhinitis: a randomized clinical trial

Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels.

A Multicenter Randomized Double-Blind 2-Week Comparison Study of Azelastine Nasal Spray 0.1% Versus Levocabastine Nasal Spray 0.05% in Patients with Moderate-to-severe Allergic Rhinitis.

Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Efficacy and Safety of Modified Yupingfeng Nasal Spray in Controlling the Recurrence of Persistent and Moderate-Severe Allergic Rhinitis: Study Protocol for a Multicenter, Open-Label, Randomized, and Parallel-Arm Trial.

A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate–Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis

The Effect of Nasal Irrigation in the Treatment of Allergic Rhinitis

Clinical Effect Analysis of Fire‐needle Acupuncture at Neiyingxiang Treating Persistent Allergic Rhinitis